Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/33728
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLavinsky, Daniel [UNIFESP]
dc.contributor.authorCardillo, Jose A. [UNIFESP]
dc.contributor.authorMelo Jr., Luiz Alberto Soares [UNIFESP]
dc.contributor.authorDare, Alessandro
dc.contributor.authorFarah, Michel Eid [UNIFESP]
dc.contributor.authorBelfort, Rubens Junior [UNIFESP]
dc.date.accessioned2016-01-24T14:16:47Z-
dc.date.available2016-01-24T14:16:47Z-
dc.date.issued2011-06-01
dc.identifierhttp://dx.doi.org/10.1167/iovs.10-6828
dc.identifier.citationInvestigative Ophthalmology & Visual Science. Rockville: Assoc Research Vision Ophthalmology Inc, v. 52, n. 7, p. 4314-4323, 2011.
dc.identifier.issn0146-0404
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/33728-
dc.description.abstractPURPOSE. To compare modified Early Treatment Diabetic Retinopathy Study (mETDRS) focal/grid laser photocoagulation with normal-density (ND-SDM) or high-density (HD-SDM) subthreshold diode-laser micropulse photocoagulation for the treatment diabetic macular edema (DME).METHODS. A prospective, randomized, controlled, double-masked clinical trial with patients with previously untreated DME and best corrected visual acuity (BCVA) worse than 20/40 and better than 20/400. Patients were randomized to receive either mETDRS focal/grid photocoagulation (42 patients), NDSDM (39 patients), or HD-SDM (42 patients). Before treatment and 1, 3, 6, and 12 months after treatment, all patients underwent ophthalmic examinations, BCVA, color fundus photography, fluorescein angiography, and optical coherence tomography (OCT).RESULTS. At 12 months, the HD-SDM group had the best improvement in BCVA (0.25 logMAR), followed by the mETDRS group (0.08 logMAR), whereas no improvements were seen in the ND-SDM group (0.03 logMAR). All groups showed statistically significant progressive reduction of central macular thickness (CMT) throughout the study (P < 0.001). the HD-SDM group exhibited the greatest CMT reduction (154 mu m), which was not significantly different from that of the mETDRS group (126 mu m; P = 0.75).CONCLUSIONS. At 1 year, the clinical performance of HD-SDM was superior to that of the mETDRS photocoagulation technique, according to the anatomic and functional measures of improvement used in this investigation. A rationale for this treatment modality as a preferable approach is suggested, and the precise role of subthreshold micropulse laser treatment may become more defined as experience grows, guided by optimized treatment guidelines and more comprehensive trials. (Clinicaltrials.gov number, NCT00552435.) (Invest Ophthalmol Vis Sci. 2011;52:4314-4323) DOI:10.1167/iovs.10-6828en
dc.format.extent4314-4323
dc.language.isoeng
dc.publisherAssoc Research Vision Ophthalmology Inc
dc.relation.ispartofInvestigative Ophthalmology & Visual Science
dc.rightsAcesso aberto
dc.titleRandomized Clinical Trial Evaluating mETDRS versus Normal or High-Density Micropulse Photocoagulation for Diabetic Macular Edemaen
dc.typeArtigo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionHosp Olhos Araraquara
dc.description.affiliationUniversidade Federal de São Paulo, EPM, São Paulo, Brazil
dc.description.affiliationHosp Olhos Araraquara, Araraquara, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, EPM, São Paulo, Brazil
dc.identifier.doi10.1167/iovs.10-6828
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000293332500051
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.